Ltd. Kck Sells 5,270,845 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 5,270,845 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

NeuroPace Stock Performance

Shares of NASDAQ:NPCE opened at $13.77 on Friday. NeuroPace, Inc. has a 12-month low of $5.45 and a 12-month high of $17.45. The company’s 50 day moving average price is $12.49 and its two-hundred day moving average price is $9.42. The firm has a market cap of $411.01 million, a PE ratio of -13.77 and a beta of 2.05. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on NPCE. UBS Group began coverage on shares of NeuroPace in a report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target on the stock. JPMorgan Chase & Co. lifted their price target on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Finally, Wells Fargo & Company boosted their price target on NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $14.80.

Hedge Funds Weigh In On NeuroPace

Hedge funds have recently added to or reduced their stakes in the stock. KCK LTD. acquired a new stake in NeuroPace during the fourth quarter worth about $58,981,000. Geode Capital Management LLC lifted its stake in NeuroPace by 1.8% in the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company’s stock valued at $3,615,000 after purchasing an additional 5,781 shares during the last quarter. Northern Trust Corp boosted its position in NeuroPace by 15.7% in the fourth quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock valued at $2,068,000 after buying an additional 25,035 shares in the last quarter. State Street Corp grew its stake in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after buying an additional 12,912 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of NeuroPace during the fourth quarter worth $1,120,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.